Cell Point

What does Cell Point do?

Cell Point (India) Ltd is a micro-cap retail company incorporated in 2013, converted to a public limited company in 2022, with no recent sales or profit data reported. It has a market cap of Rs 35 Cr, a P/E ratio of 35.00, and a dividend yield of 1.07%.

Overview: <BR>Cell Point (India) Ltd operates in the retailing industry and is classified as a micro-cap company.<BR><BR>History: <BR>Cell Point (India) Ltd was incorporated on April 10, 2013, under the name 'Cell Point (India) Private Limited' and was later converted to a public limited company on November 25, 2022. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 35 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 35.00 <BR>Industry P/E: 30 <BR>Dividend Yield: 1.07% <BR>Debt-Equity: 0.51 <BR>Return on Equity: 0.51% <BR>Price-to-Book: 0.48 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

When is the next results date for Cell Point?

No Upcoming Board Meetings

Has Cell Point declared dividend?

Yes, Cell Point (India) Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of September 19, 2024. However, the company has experienced significant price declines, resulting in negative total returns over various periods.

Cell Point (India) Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: ₹0.20<BR>- Ex-date: 19 Sep 2024<BR><BR>Dividend Yield: 1.07%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -34.26%, the dividend return was 0%, resulting in a total return of -34.26%.<BR><BR>For the 1-year period, the price return was -46.31%, the dividend return was 0.56%, leading to a total return of -45.75%.<BR><BR>Over the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, there were no changes in price or dividends, leading to a total return of 0.0%.<BR><BR>In the 5-year period, there was again no price or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Cell Point has declared a dividend, the total returns over various periods indicate significant losses in the short term, with no returns from dividends in most periods. The company appears to be struggling, as reflected in the negative price returns.

What is the technical trend for Cell Point?

As of May 12, 2025, Cell Point's trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite a mildly bullish indication from the weekly MACD and KST.

As of 12 May 2025, the technical trend for Cell Point has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages reflect a mildly bearish trend. The Bollinger Bands are bearish on both weekly and monthly time frames, and the RSI shows no signal in both time frames. The KST and Dow Theory are mildly bullish on the weekly and monthly charts, providing some support to the overall outlook. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and Bollinger Bands.

Who are the peers of the Cell Point?

Cell Point's peers include Purv Flexi, Silgo Retail, Magson Retail, Fonebox Retail, Sattva Sukun, Kotia Enterprise, Ace Men, Radhagobind Comm, and MRP Agro. In terms of management risk, Cell Point has an average rating, with its 1-year return at -47.50%, better than Purv Flexi's -54.91% but worse than Silgo Retail's 63.48%.

Peers: The peers of Cell Point are Purv Flexi, Silgo Retail, Magson Retail, Fonebox Retail, Sattva Sukun, Kotia Enterprise, Ace Men, Radhagobind Comm, MRP Agro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Fonebox Retail and MRP Agro, while Good management risk is found at Magson Retail. Average management risk is present at Cell Point, and Below Average management risk is noted at Purv Flexi, Silgo Retail, Sattva Sukun, Kotia Enterprise, Ace Men, and the rest. Growth is Excellent at Sattva Sukun, Good at Magson Retail and MRP Agro, Below Average at Cell Point, Purv Flexi, Silgo Retail, Kotia Enterprise, Ace Men, and the rest. Capital Structure is Good at Magson Retail, Sattva Sukun, and Ace Men, while Below Average is seen at Cell Point, Purv Flexi, Silgo Retail, Kotia Enterprise, and the rest.<BR><BR>Return Snapshot: Silgo Retail has the highest 1-year return at 63.48%, while Purv Flexi has the lowest at -54.91%. Cell Point's 1-year return of -47.50% is better than Purv Flexi's but worse than Silgo Retail's. Additionally, the six-month returns are negative for Purv Flexi, Fonebox Retail, and Cell Point.

Who are the top shareholders of the Cell Point?

The top shareholder of Cell Point is Mohan Prasad Panday, who holds 64.54% of the shares. Individual investors own 24.39%, with no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Cell Point are primarily the promoters, with Mohan Prasad Panday holding the largest share at 64.54%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Individual investors collectively hold 24.39% of the shares.

How big is Cell Point?

As of 24th July, Cell Point (India) Ltd has a market capitalization of 35.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for Net Sales and Net Profit for the latest 4 quarters.

As of 24th July, <BR><BR>Market Cap: Cell Point (India) Ltd has a market capitalization of 35.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest 4 quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds valued at 72.12 Cr and Total Assets amounting to 133.10 Cr.

How has been the historical performance of Cell Point?

Cell Point has shown consistent growth in net sales, reaching 324.71 Cr in March 2025, but profitability metrics have fluctuated, with operating profit declining from 19.34 Cr in March 2023 to 8.88 Cr in March 2025. Total assets increased to 137.69 Cr in March 2025, while cash flow improved to 0.00 Cr, indicating ongoing liquidity challenges.

Answer:<BR>The historical performance of Cell Point shows a steady increase in net sales over the years, reaching 324.71 Cr in March 2025, up from 321.23 Cr in March 2024, and significantly higher than 295.67 Cr in March 2023. The total operating income mirrored this trend, with a rise to 324.71 Cr in March 2025 from 321.23 Cr in the previous year. However, the operating profit (PBDIT) has seen fluctuations, peaking at 19.34 Cr in March 2023 before declining to 8.88 Cr in March 2025. Profit before tax also experienced a decline, with 2.81 Cr reported in March 2025 compared to 9.87 Cr in March 2023. Profit after tax followed a similar pattern, increasing to 2.26 Cr in March 2025 from 1.69 Cr in March 2024 but down from 6.73 Cr in March 2023. <BR><BR>In terms of assets and liabilities, total assets grew to 137.69 Cr in March 2025 from 133.10 Cr in March 2024, with total liabilities also increasing to 137.69 Cr from 133.10 Cr. The company's cash flow from operating activities was notably negative in March 2024 at -7.00 Cr, but improved to 0.00 Cr in March 2025. The net cash outflow for March 2025 was -5.00 Cr, a decline from a net inflow of 1.00 Cr in March 2024. Overall, while Cell Point has shown growth in sales and total assets, profitability metrics have fluctuated, indicating challenges in maintaining profit levels in recent periods. <BR><BR>Breakdown:<BR>Cell Point's net sales have consistently increased, reaching 324.71 Cr in March 2025, up from 321.23 Cr in March 2024, and significantly higher than previous years. The total operating income followed suit, reflecting the same growth trajectory. However, operating profit (PBDIT) peaked at 19.34 Cr in March 2023 and has since declined to 8.88 Cr in March 2025, indicating volatility in profitability. Profit before tax also decreased to 2.81 Cr in March 2025 from a higher 9.87 Cr in March 2023, while profit after tax showed a slight increase to 2.26 Cr in March 2025 from 1.69 Cr in the prior year, but was down from 6.73 Cr in March 2023. On the balance sheet, total assets rose to 137.69 Cr in March 2025, with total liabilities matching this figure, reflecting a stable financial position despite the challenges in profitability. Cash flow from operating activities improved to 0.00 Cr in March 2025 after a negative performance in the previous year, though the net cash outflow indicates ongoing liquidity challenges.

Is Cell Point overvalued or undervalued?

As of November 14, 2025, Cell Point is considered overvalued with a PE ratio of 98.49, significantly higher than its peers, and despite a recent one-week return of 8.33%, it has declined 27.1% year-to-date, indicating it is not a favorable investment at its current price.

As of 14 November 2025, the valuation grade for Cell Point has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 98.49, an EV to EBIT of 23.77, and an EV to EBITDA of 13.30, all suggesting that the stock is priced significantly higher than its earnings potential.<BR><BR>In comparison to its peers, Cell Point's valuation appears particularly high when contrasted with PTC India, which has a PE ratio of 7.52 and is rated as very attractive, and Optiemus Infra, rated as fair with a PE of 75.09. This stark difference in valuation metrics underscores the overvaluation of Cell Point. Additionally, while the stock has shown a recent one-week return of 8.33% compared to the Sensex's 1.64%, its year-to-date performance is concerning, with a decline of 27.1% against a 9.58% rise in the Sensex, further reinforcing the notion that Cell Point is not a favorable investment at its current price.

Why is Cell Point (India) Ltd falling/rising?

As of 12-May, the stock price of Cell Point (India) Ltd is 16.00, unchanged from the previous session. The stock has underperformed in the short term, with a 4.19% decline over the past week, while showing mixed performance compared to the benchmark Sensex and its sector.

As of 12-May, the stock price of Cell Point (India) Ltd is currently at 16.00, with no change from the previous trading session (0.00%). Over the past week, the stock has decreased by 4.19%, while the benchmark Sensex has fallen by 2.72%. In the last month, the stock has remained flat with a 0.00% change, compared to a 2.79% decline in the Sensex. Year-to-date, Cell Point (India) Ltd has seen a decline of 3.03%, while the Sensex has decreased by 10.52%. Over the past year, the stock has dropped by 5.04%, which is less than the Sensex's decline of 6.20%.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 2.6%. However, it is important to note that while the stock is higher than the 50-day and 100-day moving averages, it is lower than the 5-day, 20-day, and 200-day moving averages. Additionally, the broader market, represented by the BSE Small Cap index, has fallen by 12.5%, indicating a challenging environment for small-cap stocks.<BR><BR>Overall, the stock's price is not rising significantly, and its recent performance reflects a mixed picture, with some short-term underperformance relative to both the sector and the benchmark index.

Which are the latest news on Cell Point?